Gadolinium, a contrast agent used in MRI and MRA scans has been linked to a painful condition affecting the skin and joints as well as impaired brain function.
On Thursday, a law firm announced it was representing Chuck Norris in a suit against three different companies for $10 million in damages. Norris and his wife, Gena, claim that she has gadolinium deposition disease from medical scans taken five years ago. But what is gadolinium? And how controversial is its use?
READ MORE at Newsweek.com
Gadolinium chelates are widely used as contrast media for magnetic resonance imaging. The approved gadolinium-based contrast agents (GBCAs) have historically been considered safe and well tolerated when used at recommended dosing levels. However, for nearly a decade, an association between GBCA administration and the development of nephrogenic systemic fibrosis (NSF) has been recognized in patients with severe renal impairment.
READ MORE at the National Institute of Health
Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication - Retained in Body; New Class Warnings
FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.
READ MORE at FDA.gov
Today we have released our fourth research paper on gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) administered for contrast-enhanced MRIs. The paper is titled “Gadolinium Retention from Contrast MRIs in 70 Cases with Normal Renal Function – 24-hour Urine Test Results”.
READ MORE at GadoliniumToxicity.com